Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Gastroesophageal Junction Carcinoma”

49 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 49 results

Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Large-scale testing (Phase 3)Active Not RecruitingNCT04704934
What this trial is testing

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Who this might be right for
Gastric Cancer, AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Daiichi Sankyo 490
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06942767
What this trial is testing

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 100
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07287995
What this trial is testing

ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 428
Large-scale testing (Phase 3)Looking for participantsNCT07385703
What this trial is testing

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Adenocarcinoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. 752
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Testing effectiveness (Phase 2)Study completedNCT03196232
What this trial is testing

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Esophageal Carcinoma+4 more
George Albert Fisher 3
Early research (Phase 1)Study completedNCT02892123
What this trial is testing

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Who this might be right for
HER2-expressing Cancers
Jazz Pharmaceuticals 279
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Early research (Phase 1)Looking for participantsNCT06364410
What this trial is testing

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI) 48
Early research (Phase 1)Study completedNCT02572687
What this trial is testing

Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaNon-Small Cell Lung Cancer+1 more
Eli Lilly and Company 85
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Early research (Phase 1)Ended earlyNCT02283359
What this trial is testing

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Who this might be right for
Esophageal CancerGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 3
Early research (Phase 1)WithdrawnNCT02205463
What this trial is testing

KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

Who this might be right for
Esophageal CancerStomach Cancer
NYU Langone Health
Early research (Phase 1)Active Not RecruitingNCT04007744
What this trial is testing

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8+19 more
Mayo Clinic 36
Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757
What this trial is testing

Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397
What this trial is testing

Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00256321
What this trial is testing

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

Who this might be right for
Gastric CarcinomaGastroesophageal Junction Carcinoma
University of California, Irvine 4
Next Page
507
50
565